Currently Enrolling Study
Ocugen Study for Ocular Graft-versus-Host Disease
Purpose of study:
This project is being done to find out whether a new drug, brimonidine nanoemulsion, reduces the symptoms of ocular Graft-versus-Host Disease (oGVHD), and whether it causes any problems (side effects) in patients with this condition.
What is Ocular Graft-vs-Host Disease?
Ocular Graft-vs-Host Disease is a chronic autoimmune ocular disorder in patients who have received hematopoietic stem cell transplants, characterized by dry eye, pain, and redness. There are currently no FDA-approved treatments for oGVHD.
What is involved?
The study will last about 12 weeks with 5 in-clinic study visits. Study visits will include questionnaires, an eye exam, and vision testing. Because we do not know what effect the study drug has on the symptoms of oGVHD, participants will have a 2 in 3 chance of receiving the brimonidine nanoemulsion study drug and a 1 in 3 chance of receiving placebo (eyedrops that look like the drug but do not contain any real medication).
Research volunteers will receive $50 for each study visit that is completed.
- You may be eligible to participate in this study if you meet these criteria.
- You have been told by a doctor that you have ocular Graft-versus-Host Disease.
- You meet the diagnostic criteria for the study (to be determined by your study doctor).
- You have not participated in another investigational drug or device study within the last month.
- You have not had ocular surgery within the past 3 months
- You are 18 years or older.
- You are not pregnant.
Contact Katie McKenney with questions. (414) 955-7866 or email
IRB Approval: PRO####, MM/DD/YYYY
I AM INTERESTEDLEARN MORE
For patient care inquires, call us at (414) 955-2020 or use MyChart. Email is for research and education inquiries only.
Eye Institute Location
925 N. 87th St.
Milwaukee, WI 53226
(414) 955-6166 (fax)
Continuing Medical Education
Medical Education Coordinator